Aung Ko Win1, Daniel D Buchanan2, Christophe Rosty3, Robert J MacInnis4, James G Dowty1, Gillian S Dite1, Graham G Giles4, Melissa C Southey5, Joanne P Young2, Mark Clendenning2, Michael D Walsh2, Rhiannon J Walters2, Alex Boussioutas6, Thomas C Smyrk7, Stephen N Thibodeau7, John A Baron8, John D Potter9, Polly A Newcomb10, Loïc Le Marchand11, Robert W Haile12, Steven Gallinger13, Noralane M Lindor14, John L Hopper1, Dennis J Ahnen15, Mark A Jenkins1. 1. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia. 2. Cancer and Population Studies Group, Queensland Institute of Medical Research, Clive Berghofer Cancer Research Centre, Herston, Queensland, Australia. 3. Cancer and Population Studies Group, Queensland Institute of Medical Research, Clive Berghofer Cancer Research Centre, Herston, Queensland, Australia Department of Molecular and Cellular Pathology, University of Queensland, Herston, Queensland, Australia Envoi Specialist Pathologists, Herston, Queensland, Australia. 4. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia Cancer Epidemiology Centre, Cancer Council Victoria, Carlton, Victoria, Australia. 5. Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia. 6. Department of Medicine, Royal Melbourne Hospital, The University of Melbourne, Parkville, Australia Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia. 7. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA. 8. Department of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA. 9. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA School of Public Health, University of Washington, Seattle, Washington, USA Centre for Public Health Research, Massey University, Wellington, New Zealand. 10. Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA School of Public Health, University of Washington, Seattle, Washington, USA. 11. University of Hawaii Cancer Center, Honolulu, Hawaii, USA. 12. Stanford Cancer Institute, Stanford University, San Francisco, California, USA. 13. Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada Cancer Care Ontario, Toronto, Ontario, Canada. 14. Department of Health Science Research, Mayo Clinic Arizona, Scottsdale, Arizona, USA. 15. Department of Veterans Affairs, Eastern Colorado Health Care System, University of Colorado School of Medicine, Denver, Colorado, USA.
Abstract
OBJECTIVE: To estimate risk of colorectal cancer (CRC) for first-degree relatives of CRC cases based on CRC molecular subtypes and tumour pathology features. DESIGN: We studied a cohort of 33,496 first-degree relatives of 4853 incident invasive CRC cases (probands) who were recruited to the Colon Cancer Family Registry through population cancer registries in the USA, Canada and Australia. We categorised the first-degree relatives into four groups: 28,156 of 4095 mismatch repair (MMR)-proficient probands, 2302 of 301 MMR-deficient non-Lynch syndrome probands, 1799 of 271 suspected Lynch syndrome probands and 1239 of 186 Lynch syndrome probands. We compared CRC risk for first-degree relatives stratified by the absence or presence of specific tumour molecular pathology features in probands across each of these four groups and for all groups combined. RESULTS: Compared with first-degree relatives of MMR-proficient CRC cases, a higher risk of CRC was estimated for first-degree relatives of CRC cases with suspected Lynch syndrome (HR 2.06, 95% CI 1.59 to 2.67) and with Lynch syndrome (HR 5.37, 95% CI 4.16 to 6.94), but not with MMR-deficient non-Lynch syndrome (HR 1.04, 95% CI 0.82 to 1.31). A greater risk of CRC was estimated for first-degree relatives if CRC cases were diagnosed before age 50 years, had proximal colon cancer or if their tumours had any of the following: expanding tumour margin, peritumoral lymphocytes, tumour-infiltrating lymphocytes or synchronous CRC. CONCLUSIONS: Molecular pathology features are potentially useful to refine screening recommendations for first-degree relatives of CRC cases and to identify which cases are more likely to be caused by genetic or other familial factors. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: To estimate risk of colorectal cancer (CRC) for first-degree relatives of CRC cases based on CRC molecular subtypes and tumour pathology features. DESIGN: We studied a cohort of 33,496 first-degree relatives of 4853 incident invasive CRC cases (probands) who were recruited to the Colon Cancer Family Registry through population cancer registries in the USA, Canada and Australia. We categorised the first-degree relatives into four groups: 28,156 of 4095 mismatch repair (MMR)-proficient probands, 2302 of 301 MMR-deficient non-Lynch syndrome probands, 1799 of 271 suspected Lynch syndrome probands and 1239 of 186 Lynch syndrome probands. We compared CRC risk for first-degree relatives stratified by the absence or presence of specific tumour molecular pathology features in probands across each of these four groups and for all groups combined. RESULTS: Compared with first-degree relatives of MMR-proficient CRC cases, a higher risk of CRC was estimated for first-degree relatives of CRC cases with suspected Lynch syndrome (HR 2.06, 95% CI 1.59 to 2.67) and with Lynch syndrome (HR 5.37, 95% CI 4.16 to 6.94), but not with MMR-deficient non-Lynch syndrome (HR 1.04, 95% CI 0.82 to 1.31). A greater risk of CRC was estimated for first-degree relatives if CRC cases were diagnosed before age 50 years, had proximal colon cancer or if their tumours had any of the following: expanding tumour margin, peritumoral lymphocytes, tumour-infiltrating lymphocytes or synchronous CRC. CONCLUSIONS: Molecular pathology features are potentially useful to refine screening recommendations for first-degree relatives of CRC cases and to identify which cases are more likely to be caused by genetic or other familial factors. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Andrew H Beck; Ankur R Sangoi; Samuel Leung; Robert J Marinelli; Torsten O Nielsen; Marc J van de Vijver; Robert B West; Matt van de Rijn; Daphne Koller Journal: Sci Transl Med Date: 2011-11-09 Impact factor: 17.956
Authors: Kandelaria Rumilla; Karen V Schowalter; Noralane M Lindor; Brittany C Thomas; Kara A Mensink; Steven Gallinger; Spring Holter; Polly A Newcomb; John D Potter; Mark A Jenkins; John L Hopper; Tiffany I Long; Daniel J Weisenberger; Robert W Haile; Graham Casey; Peter W Laird; Loic Le Marchand; Stephen N Thibodeau Journal: J Mol Diagn Date: 2010-12-23 Impact factor: 5.568
Authors: J Young; L A Simms; K G Biden; C Wynter; V Whitehall; R Karamatic; J George; J Goldblatt; I Walpole; S A Robin; M M Borten; R Stitz; J Searle; D McKeone; L Fraser; D R Purdie; K Podger; R Price; R Buttenshaw; M D Walsh; M Barker; B A Leggett; J R Jass Journal: Am J Pathol Date: 2001-12 Impact factor: 4.307
Authors: J L Hopper; M A Jenkins; J G Dowty; G S Dite; C Apicella; L Keogh; A K Win; J P Young; D Buchanan; M D Walsh; C Rosty; L Baglietto; G Severi; K A Phillips; E M Wong; A Dobrovic; P Waring; I Winship; S J Ramus; G G Giles; M C Southey Journal: Pathology Date: 2012-02 Impact factor: 5.306
Authors: Polly A Newcomb; John Baron; Michelle Cotterchio; Steve Gallinger; John Grove; Robert Haile; David Hall; John L Hopper; Jeremy Jass; Loïc Le Marchand; Paul Limburg; Noralane Lindor; John D Potter; Allyson S Templeton; Steve Thibodeau; Daniela Seminara Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-11-02 Impact factor: 4.254
Authors: James G Dowty; Aung K Win; Daniel D Buchanan; Noralane M Lindor; Finlay A Macrae; Mark Clendenning; Yoland C Antill; Stephen N Thibodeau; Graham Casey; Steve Gallinger; Loic Le Marchand; Polly A Newcomb; Robert W Haile; Graeme P Young; Paul A James; Graham G Giles; Shanaka R Gunawardena; Barbara A Leggett; Michael Gattas; Alex Boussioutas; Dennis J Ahnen; John A Baron; Susan Parry; Jack Goldblatt; Joanne P Young; John L Hopper; Mark A Jenkins Journal: Hum Mutat Date: 2013-03 Impact factor: 4.878
Authors: María Rodríguez-Soler; Lucía Pérez-Carbonell; Carla Guarinos; Pedro Zapater; Adela Castillejo; Victor M Barberá; Miriam Juárez; Xavier Bessa; Rosa M Xicola; Juan Clofent; Luis Bujanda; Francesc Balaguer; Josep-Maria Reñé; Luisa de-Castro; José C Marín-Gabriel; Angel Lanas; Joaquín Cubiella; David Nicolás-Pérez; Alejandro Brea-Fernández; Sergi Castellví-Bel; Cristina Alenda; Clara Ruiz-Ponte; Angel Carracedo; Antoni Castells; Montserrat Andreu; Xavier Llor; José L Soto; Artemio Payá; Rodrigo Jover Journal: Gastroenterology Date: 2013-01-24 Impact factor: 22.682
Authors: Mark A Jenkins; Shinichi Hayashi; Anne-Marie O'Shea; Lawrence J Burgart; Tom C Smyrk; David Shimizu; Paul M Waring; Andrew R Ruszkiewicz; Aaron F Pollett; Mark Redston; Melissa A Barker; John A Baron; Graham R Casey; James G Dowty; Graham G Giles; Paul Limburg; Polly Newcomb; Joanne P Young; Michael D Walsh; Stephen N Thibodeau; Noralane M Lindor; Loïc Lemarchand; Steven Gallinger; Robert W Haile; John D Potter; John L Hopper; Jeremy R Jass Journal: Gastroenterology Date: 2007-04-25 Impact factor: 22.682
Authors: A M G Ali; S-J Dawson; F M Blows; E Provenzano; I O Ellis; L Baglietto; D Huntsman; C Caldas; P D Pharoah Journal: Br J Cancer Date: 2011-01-25 Impact factor: 7.640
Authors: Kosuke Mima; Reiko Nishihara; Zhi Rong Qian; Yin Cao; Yasutaka Sukawa; Jonathan A Nowak; Juhong Yang; Ruoxu Dou; Yohei Masugi; Mingyang Song; Aleksandar D Kostic; Marios Giannakis; Susan Bullman; Danny A Milner; Hideo Baba; Edward L Giovannucci; Levi A Garraway; Gordon J Freeman; Glenn Dranoff; Wendy S Garrett; Curtis Huttenhower; Matthew Meyerson; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Shuji Ogino Journal: Gut Date: 2015-08-26 Impact factor: 23.059
Authors: Rish K Pai; Beth Dudley; Eve Karloski; Randall E Brand; Neil O'Callaghan; Christophe Rosty; Daniel D Buchanan; Mark A Jenkins; Stephen N Thibodeau; Amy J French; Noralane M Lindor; Reetesh K Pai Journal: Mod Pathol Date: 2018-06-08 Impact factor: 7.842
Authors: Aung Ko Win; Jeanette C Reece; Daniel D Buchanan; Mark Clendenning; Joanne P Young; Sean P Cleary; Hyeja Kim; Michelle Cotterchio; James G Dowty; Robert J MacInnis; Katherine M Tucker; Ingrid M Winship; Finlay A Macrae; Terrilea Burnett; Loïc Le Marchand; Graham Casey; Robert W Haile; Polly A Newcomb; Stephen N Thibodeau; Noralane M Lindor; John L Hopper; Steven Gallinger; Mark A Jenkins Journal: Fam Cancer Date: 2015-12 Impact factor: 2.375
Authors: Pandu P Nugroho; Siti Alyaa S Ghozali; Daniel D Buchanan; Mia I Pisano; Jeanette C Reece Journal: J Cancer Res Clin Oncol Date: 2022-10-17 Impact factor: 4.322
Authors: Kevin J Monahan; Nicola Bradshaw; Sunil Dolwani; Bianca Desouza; Malcolm G Dunlop; James E East; Mohammad Ilyas; Asha Kaur; Fiona Lalloo; Andrew Latchford; Matthew D Rutter; Ian Tomlinson; Huw J W Thomas; James Hill Journal: Gut Date: 2019-11-28 Impact factor: 23.059